Compare · NVO vs SNY
NVO vs SNY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sanofi (SNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SNY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $167.46B, about 1.5x SNY ($113.46B).
- Over the past year, NVO is down 16.0% and SNY is down 5.4% - SNY leads by 10.6 points.
- SNY has been more active in the news (10 items in the past 4 weeks vs 7 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Sanofi
- Price
- $37.81-2.80%
- $46.52+1.01%
- Market cap
- $167.46B
- $113.46B
- 1M return
- -4.16%
- +10.88%
- 1Y return
- -15.97%
- -5.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 10
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SNY
- FDA Approval for INFILBRAY issued to GENZYME CORP A SANOFI CO
- Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients
- FDA Approval for CHILDREN'S ALLEGRA HIVES issued to CHATTEM SANOFI
- FDA Approval for RIFADIN issued to SANOFI AVENTIS US
- FDA Approval for CHILDREN'S ALLEGRA ALLERGY issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA ALLERGY issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA HIVES issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION issued to CHATTEM SANOFI
- Sanofi upgraded by BNP Paribas Exane
- SEC Form 13F-HR filed by Sanofi